Explore

Precure Selects Helix as Multiomics Lab and AI Tools Provider for Mayo Clinic Initiative

Precure Selects Helix as Multiomics Lab and AI Tools Provider for Mayo Clinic Initiative

Precure, an initiative launched by the Mayo Clinic and founding partner Thermo Fisher Scientific, has selected Helix as its multiomics laboratory and AI tools provider. This collaboration aims to generate molecular data from approximately one million biospecimens to integrate molecular insights into routine clinical care at the Mayo Clinic and other health systems. Helix will supply advanced AI tools for genomics delivery in clinical settings and biomarker-driven research, alongside population-scale multiomic capabilities, including clinical whole genome sequencing (WGS) and research-grade proteome sequencing. The objective is to create new opportunities for disease prevention, diagnosis, and treatment by linking this data with longitudinal clinical information and high-performance computing infrastructure.

Oncogenomics Revolutionizes Cancer Treatment Through Personalized Medicine

Oncogenomics Revolutionizes Cancer Treatment Through Personalized Medicine

Oncogenomics, a specialized field within personalized medicine, is transforming cancer treatment by focusing on the genomic analysis of tumors. This approach allows for the tailoring of medication regimens and therapies based on an individual's unique genetic profile. By understanding the specific genetic mutations associated with a patient's cancer, clinicians can develop more effective and targeted treatments. This method is a direct evolution from the Human Genome Project, which, completed in 2003, provided the foundational knowledge for advanced genetic testing. Oncogenomics is now a critical component in identifying metabolic programs linked to drug sensitivity, such as oxaliplatin in gastric cancer, offering valuable prognostic information and improving patient outcomes through sophisticated molecular analysis.

Microbiome Therapeutics Market Poised for Significant Growth Driven by Personalized Medicine and AI Integration

Microbiome Therapeutics Market Poised for Significant Growth Driven by Personalized Medicine and AI Integration

Microbiome Therapeutics Market Poised for Significant Growth Driven by Personalized Medicine and AI Integration

CellsBin Secures Series A Financing Led by 108 BioCapital to Advance Rare-Cell Intelligence Platform

CellsBin Secures Series A Financing Led by 108 BioCapital to Advance Rare-Cell Intelligence Platform

CellsBin Secures Series A Financing Led by 108 BioCapital to Advance Rare-Cell Intelligence Platform

CellsBin Secures Series A Financing from 108 BioCapital to Advance Rare-Cell Intelligence Platform

CellsBin Secures Series A Financing from 108 BioCapital to Advance Rare-Cell Intelligence Platform

CellsBin Secures Series A Financing from 108 BioCapital to Advance Rare-Cell Intelligence Platform

US FDA advisers endorse Grail cancer test's benefits in key vote

US FDA advisers endorse Grail cancer test's benefits in key vote

By Padmanabhan Ananthan and Kamal Choudhury Sept 23 (Reuters) - A panel of outside experts advising the US FDA said on Wednesday the benefits of Grail's blood-based cancer detection test outweigh its risks, paving the way for a potential landmark approval in cancer screening.

Pharmacogenomic Testing Offers Insights for Psychiatric Medication Management

Pharmacogenomic Testing Offers Insights for Psychiatric Medication Management

Pharmacogenomic testing, also known as psychiatric genetic testing, is emerging as a tool to help understand how an individual's genetic makeup influences their response to certain medications. These tests analyze genetic differences that can affect how the body metabolizes or reacts to specific drugs. While the FDA recognizes pharmacogenomic biomarkers for a number of psychiatric medications, it is crucial to understand that this testing is not a definitive predictor of medication efficacy. It provides additional information that can assist healthcare providers in making more informed decisions regarding medication selection and dosing, particularly when patients have struggled with multiple medications or experienced significant side effects. The National Institute of Mental Health highlights that individuals respond differently to psychiatric medications, and finding the right treatment often involves careful assessment, evidence-based prescribing, monitoring, and adjustments based on individual respons...

Oracle Introduces New Oncology EHR to Enhance Cancer Care

Oracle Introduces New Oncology EHR to Enhance Cancer Care

Oracle has announced the launch of its Oracle Health Oncology EHR, a new electronic health record solution specifically designed for cancer care. This system builds upon Oracle's existing AI-powered ambulatory EHR and integrates oncology-specific workflows, AI-fueled clinical intelligence from various data sources, and connected patient information. The goal is to support patient care comprehensively, from initial diagnosis through treatment and follow-up. According to Seema Verma, executive vice president and general manager, Oracle Health and Life Sciences, the Oracle Health Oncology EHR aims to consolidate patient information and provide personalized treatment recommendations, allowing clinicians to focus more on patient care. The system is designed to address the complexities of cancer treatment, which often involves rapidly changing plans, chemotherapy regimens, laboratory and imaging results, medications, referrals, and insurance requirements across multiple care settings.

Artificial Intelligence Transforms Gene Therapy Development, Addressing Key Challenges in U.S. Healthcare

Artificial Intelligence Transforms Gene Therapy Development, Addressing Key Challenges in U.S. Healthcare

Artificial Intelligence (AI) is revolutionizing the field of gene therapy, impacting every stage from target discovery to clinical translation. AI technologies, including machine learning, deep learning, and generative AI, are being applied to analyze vast amounts of biological data generated by high-throughput sequencing and multi-omics platforms. This allows for more efficient identification of disease-causing genes, optimization of genome-editing strategies like CRISPR-Cas systems, and the design of novel viral capsids and synthetic delivery systems. For instance, AI-guided directed evolution is significantly reducing the experimental search space for vectors with improved tissue-specificity and immune evasion capabilities. In manufacturing, AI models are being developed to monitor and control bioprocess parameters, aiming to improve the yield and consistency of complex biological products such as viral vectors. The U.S. Food and Drug Administration (FDA) is actively adapting its regulatory frameworks t...

Tempus AI Anticipates Significant Growth Driven by Pricing Changes and Data Licensing Expansion

Tempus AI Anticipates Significant Growth Driven by Pricing Changes and Data Licensing Expansion

Tempus AI Anticipates Significant Growth Driven by Pricing Changes and Data Licensing Expansion

Precure Selects Helix as Multiomics Lab and AI Tools Provider to Integrate Molecular Insights into Clinical Care

Precure Selects Helix as Multiomics Lab and AI Tools Provider to Integrate Molecular Insights into Clinical Care

Precure, a new initiative launched by the Mayo Clinic and founding partner Thermo Fisher Scientific, has selected Helix as its multiomics laboratory and AI tools provider. This collaboration aims to generate molecular data from approximately one million biospecimens to accelerate the integration of molecular insights into routine clinical care at the Mayo Clinic and other health systems. Helix will provide advanced AI tools for delivering genomics into the clinic and biomarker-driven research, alongside population-scale multiomic capabilities, including clinical whole genome sequencing (WGS) and research-grade proteome sequencing. The objective is to create new opportunities for disease prevention, diagnosis, and treatment by linking this molecular data with longitudinal clinical information and high-performance computing infrastructure. This initiative builds upon the Mayo Clinic's Tapestry study, which utilized Helix's Exome+ sequencing technology with 100,000 participants.

Pharmacogenomics Services Market Expected to Exceed 10% CAGR by 2033, Driven by Personalized Medicine and Declining Sequencing Costs

Pharmacogenomics Services Market Expected to Exceed 10% CAGR by 2033, Driven by Personalized Medicine and Declining Sequencing Costs

The pharmacogenomics services market is experiencing rapid expansion, projected to grow at a compound annual growth rate (CAGR) exceeding 10% between 2026 and 2033. This growth is primarily fueled by the decreasing cost of genomic sequencing, which makes broader clinical adoption more feasible. The market is also benefiting from a surge in personalized medicine initiatives and increasing regulatory support for companion diagnostics. Key industry players, including established diagnostics giants like Abbott, Roche, Thermo Fisher, Illumina, and QIAGEN, are supplying high-throughput sequencing platforms and diagnostic assays. Clinical delivery is dominated by Quest Diagnostics and LabCorp, while companies such as Myriad Genetics, Exact Sciences, and 23andMe are expanding consumer access to genetic insights for drug metabolism. New entrants like Dynamic DNA Laboratories and Admera Health are focusing on rapid, targeted panels, contributing to the market's diversification and accessibility. The integration of p...